Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Since coronavirus disease-2019 (COVID-19) outbreak in January 2020, several pieces of evidence suggested an association between the spectrum of Guillain–Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most findings were reported in the form of case reports or case series, whereas a comprehensive overview is still lacking. We conducted a systematic review and searched for all published cases until July 20th 2020. We included 73 patients reported in 52 publications. A broad age range was affected (mean 55, min 11–max 94 years) with male predominance (68.5%). Most patients showed respiratory and/or systemic symptoms, and developed GBS manifestations after COVID-19. However, asymptomatic cases for COVID-19 were also described. The distributions of clinical variants and electrophysiological subtypes resemble those of classic GBS, with a higher prevalence of the classic sensorimotor form and the acute inflammatory demyelinating polyneuropathy, although rare variants like Miller Fisher syndrome were also reported. Cerebrospinal fluid (CSF) albuminocytological dissociation was present in around 71% cases, and CSF SARS-CoV-2 RNA was absent in all tested cases. More than 70% of patients showed a good prognosis, mostly after treatment with intravenous immunoglobulin. Patients with less favorable outcome were associated with a significantly older age in accordance with previous findings regarding both classic GBS and COVID-19. COVID-19-associated GBS seems to share most features of classic post-infectious GBS and possibly the same immune-mediated pathogenetic mechanisms. Nevertheless, more extensive epidemiological studies are needed to clarify these issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A typology of reviews: an analysis of 14 review types and associated methodologies
Grant, M. J., & Booth, A. (2009) · Health Information & Libraries Journal · doi:10.1111/j.1471-1842.2009.00848.x · Cited by 10,817
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1127 · Cited by 7,166
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
Jin, J.-M., Bai, P., He, W., Wu, F., Liu, X.-F., Han, D.-M., Liu, S., & Yang, J.-K. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00152 · Cited by 2,325
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Guillain–Barré Syndrome Associated with SARS-CoV-2
Toscano, G., Palmerini, F., Ravaglia, S., Ruiz, L., Invernizzi, P., Cuzzoni, M. G., Franciotta, D., Baldanti, F., Daturi, R., Postorino, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2009191 · Cited by 1,260
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Paterson, R. W., Brown, R. L., Benjamin, L., Nortley, R., Wiethoff, S., Bharucha, T., Jayaseelan, D. L., Kumar, G., Raftopoulos, R. E., Zambreanu, L., et al. (2020) · Brain · doi:10.1093/brain/awaa240 · Cited by 1,124
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?
Zhao, H., Shen, D., Zhou, H., Liu, J., & Chen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30109-5 · Cited by 993
Diagnosis and management of Guillain–Barré syndrome in ten steps
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0250-9 · Cited by 910
Miller Fisher syndrome and polyneuritis cranialis in COVID-19
Gutiérrez-Ortiz, C., Méndez-Guerrero, A., Rodrigo-Rey, S., San Pedro-Murillo, E., Bermejo-Guerrero, L., Gordo-Mañas, R., de Aragón-Gómez, F., & Benito-León, J. (2020) · Neurology · doi:10.1212/wnl.0000000000009619 · Cited by 810
Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria
Fokke, C., van den Berg, B., Drenthen, J., Walgaard, C., van Doorn, P. A., & Jacobs, B. C. (2014) · Brain · doi:10.1093/brain/awt285 · Cited by 792
Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review
Montalvan, V., Lee, J., Bueso, T., De Toledo, J., & Rivas, K. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.105921 · Cited by 647
Guillain Barre syndrome associated with COVID-19 infection: A case report
Sedaghat, Z., & Karimi, N. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.04.062 · Cited by 575
Guillain–Barré Syndrome Associated with Zika Virus Infection in Colombia
Parra, B., Lizarazo, J., Jiménez-Arango, J. A., Zea-Vera, A. F., González-Manrique, G., Vargas, J., Angarita, J. A., Zuñiga, G., Lopez-Gonzalez, R., Beltran, C. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605564 · Cited by 574
Neurological complications during treatment of middle east respiratory syndrome
Kim, J.-E., Heo, J.-H., Kim, H.-O., Song, S.-H., Park, S.-S., Park, T.-H., Ahn, J.-Y., Kim, M.-K., & Choi, J.-P. (2017) · Journal of Clinical Neurology · doi:10.3988/jcn.2017.13.3.227 · Cited by 497
COVID‐19: A Global Threat to the Nervous System
Koralnik, I. J., & Tyler, K. L. (2020) · Annals of Neurology · doi:10.1002/ana.25807 · Cited by 464
Association between age and clinical characteristics and outcomes of COVID-19
Liu, Y., Mao, B., Liang, S., Yang, J.-W., Lu, H.-W., Chai, Y.-H., Wang, L., Zhang, L., Li, Q.-H., Zhao, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01112-2020 · Cited by 427 · cited 1×
“In this regard, cases with no improvement or unfavorable outcome showed, in comparison to those with a good prognosis, an older age, confirming similar findings both in classic GBS [58, 88] and in COVID-19 [89], and a slightly higher frequency (without reaching a statistical significance) of past or concurrent COVID-1…”
ResultEngland, J. (1990) · Annual Review of Medicine · doi:10.1146/annurev.med.41.1.1 · Cited by 408
Zhou, Z., Kang, H., Li, S., & Zhao, X. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09929-7 · Cited by 397
Guillain-Barré syndrome related to COVID-19 infection
Alberti, P., Beretta, S., Piatti, M., Karantzoulis, A., Piatti, M. L., Santoro, P., Viganò, M., Giovannelli, G., Pirro, F., Montisano, D. A., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000741 · Cited by 335
Prediction of respiratory insufficiency in Guillain‐Barré syndrome
Walgaard, C., Lingsma, H. F., Ruts, L., Drenthen, J., van Koningsveld, R., Garssen, M. J. P., van Doorn, P. A., Steyerberg, E. W., & Jacobs, B. C. (2010) · Annals of Neurology · doi:10.1002/ana.21976 · Cited by 322
Desforges, M., Le Coupanec, A., Brison, É., Meessen-Pinard, M., & Talbot, P. J. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-81-322-1777-0_6 · Cited by 281
Dalakas, M. C. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000781 · Cited by 253
Guillain-Barré Syndrome associated with SARS-CoV-2 infection
Virani, A., Rabold, E., Hanson, T., Haag, A., Elrufay, R., Cheema, T., Balaan, M., & Bhanot, N. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00771 · Cited by 252
Diagnostic and Classification Criteria for the Guillain-Barré Syndrome
van der Meché, F. G. A., van Doorn, P. A., Meulstee, J., & Jennekens, F. G. I. (2001) · European Neurology · doi:10.1159/000052111 · Cited by 239
Guillain-Barré syndrome following COVID-19: new infection, old complication?
Padroni, M., Mastrangelo, V., Asioli, G. M., Pavolucci, L., Abu-Rumeileh, S., Piscaglia, M. G., Querzani, P., Callegarini, C., & Foschi, M. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09849-6 · Cited by 199
Self-citationCOVID-19 may induce Guillain–Barré syndrome
Camdessanche, J.-P., Morel, J., Pozzetto, B., Paul, S., Tholance, Y., & Botelho-Nevers, E. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.04.003 · Cited by 189
Guillain‐Barr é syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature
Scheidl, E., Canseco, D. D., Hadji‐Naumov, A., & Bereznai, B. (2020) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12382 · Cited by 185
Ottaviani, D., Boso, F., Tranquillini, E., Gapeni, I., Pedrotti, G., Cozzio, S., Guarrera, G. M., & Giometto, B. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04449-8 · Cited by 179
Kieseier, B. C., Mathey, E. K., Sommer, C., & Hartung, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0027-2 · Cited by 172
Wang, L., Shen, Y., Li, M., Chuang, H., Ye, Y., Zhao, H., & Wang, H. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09974-2 · Cited by 172
Covid-19 and Guillain-Barré syndrome: More than a coincidence!
Otmani, H. E., Moutawakil, B. E., Rafai, M. A., Benna, N. E., Kettani, C. E., Soussi, M., Mdaghri, N. E., Barrou, H., & Àfif, H. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.04.007 · Cited by 136
COVID-19–Associated Miller Fisher Syndrome: MRI Findings
Lantos, J. E., Strauß, S., & Lin, E. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6609 · Cited by 131
Caamaño, D. S. J., & Beato, R. A. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.05.016 · Cited by 128
Guillain-Barré syndrome as a complication of SARS-CoV-2 infection
Coen, M., Jeanson, G., Almeida, L., Hübers, A., Stierlin, F., Najjar, I., Ongaro, M., Moulin, K., Makrygianni, M., Leemann, B., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.074 · Cited by 117
Critical illness polyneuropathy and myopathy in the intensive care unit
Zink, W., Kollmar, R., & Schwab, S. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.75 · Cited by 116
Cranial neuropathies and COVID-19: Neurotropism and autoimmunity
Costello, F., & Dalakas, M. C. (2020) · Neurology · doi:10.1212/wnl.0000000000009921 · Cited by 112
Guillain–Barré Syndrome (42 Cases) Occurring During a Zika Virus Outbreak in French Polynesia
Watrin, L., Ghawche, F., Larre, P., Neau, J., Mathis, S., & Fournier, E. (2016) · Medicine · doi:10.1097/md.0000000000003257 · Cited by 110
Paybast, S., Gorji, R., & Mavandadi, S. (2020) · The Neurologist · doi:10.1097/nrl.0000000000000291 · Cited by 103
Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication
Webb, S., Wallace, V. C. J., Martín-López, D., & Yogarajah, M. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-236182 · Cited by 102
Khalifa, M. B., Zakaria, F., Ragab, Y., Saad, A. E., Bamaga, A. K., Emad, Y., & Rasker, J. J. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa086 · Cited by 100
Miller‐Fisher syndrome after SARS‐CoV‐2 infection
Bueno, J. A. R., Trujillo, L. G., Urbaneja, P., Ciano-Petersen, N. L., Postigo-Pozo, M. J., Martínez‐Tomás, C., & Serrano-Castro, P. J. (2020) · European Journal of Neurology · doi:10.1111/ene.14383 · Cited by 98
Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19
Ameres, M., Brandstetter, S., Toncheva, A. A., Kabesch, M., Leppert, D., Kuhle, J., & Wellmann, S. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10050-y · Cited by 97
Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
Brettschneider, J., Petzold, A., Süßmuth, S. D., & Tumani, H. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0097-x · Cited by 88
Self-citationClinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016
Dirlikov, E., Major, C. G., Medina, N. A., Lugo-Robles, R., Matos, D., Muñoz‐Jordán, J. L., Colón, C., Garcı́a, M., Segarra, M. O., Malave, G., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1058 · Cited by 85
Manganotti, P., Bellavita, G., D’Acunto, L., Tommasini, V., Fabris, M., Sartori, A., Bonzi, L., Stella, A. B., & Pesavento, V. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26289 · Cited by 85
Post SARS-CoV-2 Guillain-Barré syndrome
Arnaud, S., Budowski, C., Tin, S. N. W., & Degos, B. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.05.003 · Cited by 84
Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2
Manganotti, P., Pesavento, V., Stella, A. B., Bonzi, L., Campagnolo, E., Bellavita, G., Fabris, B., & Luzzati, R. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-020-00858-9 · Cited by 78
Guillain–Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection
Saldaña, A. S., Gil, Á. L., Liesa, J. L. C., Caballo, M. R. B., Haddad-Garay, M., Rivero-Celada, D., & Ponz, M. S. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0213 · Cited by 75
Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection
Chan, J. L., Ebadi, H., & Sarna, J. R. (2020) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2020.106 · Cited by 72
SARS‐CoV‐2 and Guillain–Barré syndrome: AIDP variant with a favourable outcome
Lascano, A. M., Epiney, J., Coen, M., Serratrice, J., Bernard‐Valnet, R., Lalive, P. H., Küntzer, T., & Hübers, A. (2020) · European Journal of Neurology · doi:10.1111/ene.14368 · Cited by 72
COVID-19–Associated Bifacial Weakness with Paresthesia Subtype of Guillain-Barré Syndrome
Hutchins, K. L., Jansen, J. H., Comer, A. D., Scheer, R. V., Zahn, G. S., Capps, A. E., Weaver, L., & Koontz, N. A. (2020) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6654 · Cited by 62
Lewis, R. A., & Arcila-Londono, X. (2012) · Seminars in Neurology · doi:10.1055/s-0032-1329196 · Cited by 58
Guillain–Barré syndrome after SARS‐CoV‐2 infection
Kilinc, D., van de Pasch, S., Doets, A. Y., Jacobs, B. C., van Vliet, J., & Garssen, M. P. J. (2020) · European Journal of Neurology · doi:10.1111/ene.14398 · Cited by 54
Guillain-Barré syndrome associated with COVID-19 infection: a case from the UK
Tiet, M. Y., & AlShaikh, N. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-236536 · Cited by 53
Síndrome de Guillain-Barré fatal tras infección por el virus SARS-CoV-2
Marta-Enguita, J., Rubio-Baines, I., & Gastón-Zubimendi, I. (2020) · Neurología · doi:10.1016/j.nrl.2020.04.004 · Cited by 51
Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2
Helbok, R., Beer, R., Löscher, W. N., Boesch, S., Reindl, M., Hornung, R., Schiefecker, A. J., Deisenhammer, F., & Pfausler, B. (2020) · European Journal of Neurology · doi:10.1111/ene.14388 · Cited by 50
Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report
Farzi, M. A., Ayromlou, H., Jahanbakhsh, N., Bavil, P. H., Janzadeh, A., & Shayan, F. K. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577294 · Cited by 49
Síndrome de Guillain-Barré asociado a infección por SARS-CoV-2
Galán, A. V., Saucedo, P. D. S., Postigo, F. P., & Botia-Paniagua, E. (2020) · Neurología · doi:10.1016/j.nrl.2020.04.007 · Cited by 47
Fatal Guillain-Barre syndrome after infection with SARS-CoV-2
Marta-Enguita, J., Rubio-Baines, I., & Gastón-Zubimendi, I. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.04.004 · Cited by 45
COVID‐19 polyradiculitis in 24 patients without SARS‐CoV‐2 in the cerebro‐spinal fluid
Finsterer, J., Scorza, F. A., & Ghosh, R. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26121 · Cited by 34
Guillain-Barré Syndrome Associated With COVID-19
Ebrahimzadeh, S. A., Ghoreishi, A., & Rahimian, N. (2020) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000879 · Cited by 32
Guillain-Barré syndrome and SARS-CoV-2
Lampe, A. K., Winschel, A., Lang, C., & Steiner, T. (2020) · Neurological Research and Practice · doi:10.1186/s42466-020-00066-0 · Cited by 28
Mozhdehipanah, H., Paybast, S., & Gorji, R. (2020) · International Clinical Neuroscience Journal · doi:10.34172/icnj.2020.18 · Cited by 25
Cited by
LaRovere, K. L., Riggs, B. J., Poussaint, T. Y., Young, C. C., Newhams, M. M., Maamari, M., Walker, T. C., Singh, A. R., Dapul, H., Hobbs, C. V., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0504 · Cited by 396
Harapan, B. N., & Yoo, H. J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10406-y · Cited by 359
Systemic and organ-specific immune-related manifestations of COVID-19
Ramos-Casals, M., Brito-Zerón, P., & Mariette, X. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00608-z · Cited by 309
Neuromuscular Diseases Care in the Era of COVID-19
Bertran Recasens, B., & Rubio, M. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.588929 · Cited by 43
“Plasmapheresis and intravenous immunoglobulins (IVIG) do not appear to increase the risk of infections, probably because they are often given in short courses, although long-term effect is unknown (30).”
BackgroundInfluentialImmune-Mediated Mechanisms of COVID-19 Neuropathology
Dunai, C., Collie, C., & Michael, B. D. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.882905 · Cited by 22
Metadata
- Authors
- Abu-Rumeileh, S., Abdelhak, A., Foschi, M., Tumani, H., & Otto, M.
- Venue
- Journal of Neurology
- Published
- 2020-08-25
- Volume
- 268
- Issue
- 4
- Pages
- 1133-1170
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W3080624977
- Cited by
- 419
- References
- 65
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.